Bio-Conference Calender

Following year-on-year success, CHI presents Cancer Biologics 2012 http://www.triconference.com/click-thru/110293/?email=jayantimishra02@gmail.com, a 3-day event based on in-depth research with experts in the field. In response to overwhelming interest, an entire day is devoted to antibody-drug

...

conjugates focusing on target discovery, site-specific conjugation, payloads and linkers, with case studies ranging from discovery to clinical.

Advances with multi-specific antibodies, combination therapies, immunotherapy and adoptive T cell therapy will be presented together with talks on enhancing effector function and PKPD. There will be a strong focus on translational studies from pre-clinical to clinical in successful case studies with a range of biologics. The FDA presents interesting findings on patient selection and mechanisms of drug resistance.

Pioneering developments on antibody drug conjugates will be presented by Pfizer, Takeda San Francisco, Seattle Genetics, ImmunoGen, Synthon, Ambrx, ImmunGene and Oxford Biotherapeutics. In addition there will be ground breaking case studies from Micromet, Genmab and Immunocore on multi-specifics; from Abbott, Symphogen and Aveo on combination therapies; from Adaptimmune, BMS and Biovest on Immunotherapy and adoptive T cell therapy; from ImmunGene, MacroGenics, CovX and Almac Discovery on enhancing effector function, and from Genentech, ImmunoGen and Abbott on pre-clinical to clinical transitions.

For full program details and to register, visit www.triconference.com/cancer-biologics http://www.triconference.com/click-thru/110293/.

I would like to remind you that the early registration discount ends on November 18.